NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 26 to 50 of 1213

Display Results as:

Addressing Unmet Needs in Persons with Dementia to Decrease Behavioral Symptoms and Improve Quality of Life (R01 Clinical Trial Optional) - PA-18-147

Organization: NINR 

Posting Date: 11-07-2017 

Expiration Date: 01-08-2020 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research addressing behavioral and psychological symptoms of dementia (BPSD) and the association of BPSD with unmet physical, social, or environmental needs in persons with dementia. 

Addressing Unmet Needs in Persons with Dementia to Decrease Behavioral Symptoms and Improve Quality of Life (R21 Clinical Trial Optional) - PA-18-165

Organization: NINR 

Posting Date: 11-07-2017 

Expiration Date: 01-08-2020 

Activity Code: R21 

Summary: The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research addressing behavioral and psychological symptoms of dementia (BPSD) and the association of BPSD with unmet physical, social, or environmental needs in persons with dementia. 

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01) - PA-17-041

Organization: NIMHD 

Posting Date: 11-01-2016 

Expiration Date: 01-08-2020 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.  

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R21) - PA-17-042

Organization: NIMHD 

Posting Date: 11-01-2016 

Expiration Date: 01-08-2020 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory and developmental research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations  

Administrative Supplement for Research on Sex/Gender Influences (Admin Supp - Clinical Trial Optional) - PA-18-658

Organization: ORWH 

Posting Date: 02-13-2018 

Expiration Date: 03-27-2018 

Activity Code: (Admin Supp) 

Summary: The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences in human health and illness, including basic, preclinical, clinical, translational, and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research. 

Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp) - PA-17-442

Organization: NINDS 

Posting Date: 07-28-2017 

Expiration Date: 11-01-2019 

Activity Code: (Admin Supp) 

Summary: This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances)  

Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supp) - PA-16-013

Organization: NCCIH  (formerly NCCAM)

Posting Date: 10-26-2015 

Expiration Date: 09-02-2018 

Activity Code: (Admin Supp) 

Summary: NCCIH encourages applications for administrative supplements to NCCIH-supported awards (see relevant Activity Codes above) to support complementary health practitioners in an intensive supervised clinical research experience that will lead to a better understanding of and practical experience in complementary and integrative health research. For this FOA, clinicians may include (but are not limited to) licensed acupuncturists, chiropractors, naturopathic medicine practitioners, and massage therapists. Funding is available for one year with an option to renew for a second year. to conduct clinical research associated with the parent program. This initiative is focused on providing a research experience for complementary health practitioners and is not intended to support clinical residency training or other clinical practitioner training. 

Administrative Supplements for Research on Dietary Supplements (Admin Supp) - PA-17-307

Organization: ODS 

Posting Date: 06-07-2017 

Expiration Date: 04-16-2018 

Activity Code: (Admin Supp) 

Summary: This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention. Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease. This FOA will not support new clinical trials.  

Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supplement) - PA-17-326

Organization: NINDS 

Posting Date: 07-18-2017 

Expiration Date: 09-19-2019 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) announces the continuation of the U.S. entity of the U.S.-Japan Brain Research Cooperative Program (BRCP). This administrative supplement program will provide funds to research projects that are currently supported by the participating NIH Institutes and Centers. 

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Admin Supp) - PA-16-287

Organization: NIH 

Posting Date: 05-24-2016 

Expiration Date: 02-25-2018 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. 

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional) - PA-18-591

Organization: NIH 

Posting Date: 01-25-2018 

Expiration Date: 01-26-2021 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm. 

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Suppl - Clinical Trial Not Allowed) - PA-18-496

Organization: NCI 

Posting Date: 12-15-2017 

Expiration Date: 03-02-2018 

Activity Code: (Admin Supp) 

Summary: This administrative supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials. 

Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) - PA-17-138

Organization: NCI 

Posting Date: 01-26-2017 

Expiration Date: 03-29-2018 

Activity Code: (Admin Supp) 

Summary: This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as drivers of childhood cancers, this FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations to perform research within the scientific scope of the parent grant that will lead to better understanding of the mechanisms of action of fusion oncoproteins as drivers of childhood sarcomas, brain cancers, and high risk leukemias. 

Administrative supplements for validation studies of analytical methods for dietary supplements and natural products (Admin. Suppl.) - PA-17-447

Organization: ODS 

Posting Date: 08-01-2017 

Expiration Date: 04-16-2018 

Activity Code: (Admin Supp) 

Summary: The reproducibility and comparability of dietary supplement research is enhanced through rigorous analytical characterization of key experimental materials. The publication of analytical methods which have been thoroughly validated for specific, precise, accurate, and sensitive quantitative determination of chemical constituents of dietary supplements therefore makes critical contributions to the rigor and reproducibility of biomedical research. This FOA will build on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of relevant quantitative analytical methods. The methods proposed for validation must be used to identify and quantify chemical constituents (active or marker chemical compounds, adulterants, contaminants) or metabolites thereof in experimental reagents, raw materials, and/or clinical specimens (for example urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grants specific aims. Candidate constituents for quantitative method validation studies may include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.  

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) - RFA-CA-18-005

Organization: NCI 

Posting Date: 11-20-2017 

Expiration Date: 09-29-2018 

Activity Code: R33 

Summary: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. 

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) - RFA-CA-18-003

Organization: NCI 

Posting Date: 11-20-2017 

Expiration Date: 09-29-2018 

Activity Code: R33 

Summary: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are non-responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.  

Advanced Development of Informatics Technologies for Cancer Research and Management (U24) - PAR-15-331

Organization: NCI 

Posting Date: 08-18-2015 

Expiration Date: 11-21-2018 

Activity Code: U24 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.  

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 - Clinical Trial Optional) - PAR-18-644

Organization: NIA 

Posting Date: 02-08-2018 

Expiration Date: 09-08-2019 

Activity Code: R33 

Summary: This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. 

Advances in Patient Safety through Simulation Research (R18) - PA-16-420

Organization: AHRQ 

Posting Date: 09-06-2016 

Expiration Date: 01-26-2022 

Activity Code: R18 

Summary: The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care. Simulation in health care serves multiple purposes. As a training technique, it exposes individuals and teams to realistic clinical challenges through the use of mannequins, task trainers, virtual reality, standardized patients or other forms, and allows participants to experience in real-time the consequences of their decisions and actions. The principal advantage of simulation is that it provides a safe environment for health care practitioners to acquire valuable experience without putting patients at risk. Simulation also can be used as a test-bed to improve clinical processes and to identify failure modes or other areas of concern in new procedures and technologies that might otherwise be unanticipated and serve as threats to patient safety. Yet another application of simulation focuses on the establishment of valid and reliable measures of clinical performance competency and their potential use for credentialing and certification purposes. The foremost aim of the announcement is to advance patient safety. Keeping this aim in mind, applications that address a variety of simulation techniques, clinical settings, provider groups, priority populations, and patient conditions are welcomed. 

Advances in Polycystic Kidney Disease (R01) - PA-16-159

Organization: NIDDK 

Posting Date: 03-30-2016 

Expiration Date: 05-08-2019 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to increase investigator interest in basic and applied investigations of the etiology and pathogenesis of Polycystic Kidney Disease (PKD), in both its autosomal dominant and autosomal recessive forms.The ultimate aim is to facilitate PKD-related research studies, which will provide the basis for new therapeutic approaches.  

Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed) - PAR-18-505

Organization: NIMH 

Posting Date: 12-18-2017 

Expiration Date: 01-08-2021 

Activity Code: R01 

Summary: This funding opportunity announcement (FOA) encourages research grant applications to develop novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function into phenotypic assays, with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints to accelerate basic discovery and support target identification and therapeutic development efforts. 

Advancing Erythroid Cell Biology (R01) - PA-16-039

Organization: NIDDK 

Posting Date: 11-20-2015 

Expiration Date: 01-08-2019 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages investigator-initiated applications that propose hypothesis-driven research using erythroid cells.The aim of this program is to support research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components function to achieve normal erythropoiesis.Components include genes that are expressed (transcriptome) in erythroid cells, either during development or during differentiation, chemical changes to DNA and histone proteins (epigenome) and the proteins (proteome) that are translated in erythroid cells, including post-translational modifications or subcellular localizations that are unique to erythroid cells.A long range goal of this program is to generate a concise description of erythropoiesis that unifies genetics, molecular processes and cytokine determinants in the erythroid lineages so that new therapeutics may be developed to measure and combat anemia. 

Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) - PA-15-135

Organization: NIDCR 

Posting Date: 03-09-2015 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.  

Advancing Our Understanding of the Brain Epitranscriptome (R21) - PAR-17-152

Organization: NIMH 

Posting Date: 02-03-2017 

Expiration Date: 05-08-2020 

Activity Code: R21 

Summary: The "epitranscriptome" refers to chemical modifications of RNA molecules. RNA modifications in the brain have been reported to regulate the fate and function of both coding and noncoding RNAs and are emerging as a critical element of cellular function. The purpose of this initiative is to stimulate research into the functions of modified RNAs in the brain and in the associated modification proteins that act on RNA (readers, writers, and erasers) that play a role in basic neurobiological and behavioral processes implicated in mental and substance use disorders.  

Advancing Patient Safety Implementation through Safe Medication Use Research (R18) - PA-16-421

Organization: AHRQ 

Posting Date: 09-06-2016 

Expiration Date: 09-26-2019 

Activity Code: R18 

Summary: The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top